ARK Genomic Revolution ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
ARK Genomic Revolution ETF ARKG
Morningstar’s Analysis ARKG
Will ARKG outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 58.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Twist Bioscience Corp | 8.75 | 209M | Healthcare |
10x Genomics Inc Ordinary Shares - Class A | 8.73 | 209M | Healthcare |
Tempus AI Inc Class A common stock | 8.36 | 200M | Healthcare |
Absci Corp | 5.56 | 133M | Healthcare |
CRISPR Therapeutics AG | 5.22 | 125M | Healthcare |
Guardant Health Inc | 4.88 | 117M | Healthcare |
Natera Inc | 4.71 | 113M | Healthcare |
Illumina Inc | 4.69 | 112M | Healthcare |
Eli Lilly and Co | 3.92 | 94M | Healthcare |
Beam Therapeutics Inc | 3.69 | 88M | Healthcare |